Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
Public ClinicalTrials.gov record NCT02792218. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis
Study identification
- NCT ID
- NCT02792218
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 930 participants
Conditions and interventions
Conditions
Interventions
- Ofatumumab subcutaneous injection Drug
- Teriflunomide-matching placebo capsules Drug
- Teriflunomide capsule Drug
- Matching placebo of ofatumumab subcutaneous injections Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 20, 2016 (Actual)
- Primary completion
- Jul 5, 2019 (Actual)
- Completion
- Jul 20, 2020 (Actual)
- Last update posted
- Oct 1, 2021
2016 – 2020
United States locations
- U.S. sites
- 56
- U.S. states
- 24
- U.S. cities
- 53
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Phoenix | Arizona | 85013 | — |
| Novartis Investigative Site | Berkeley | California | 94705 | — |
| Novartis Investigative Site | Fullerton | California | 92835 | — |
| Novartis Investigative Site | Sacramento | California | 95817 | — |
| Novartis Investigative Site | Washington D.C. | District of Columbia | 20007 | — |
| Novartis Investigative Site | Atlantis | Florida | 33462-6608 | — |
| Novartis Investigative Site | Delray Beach | Florida | 33445 | — |
| Novartis Investigative Site | Hollywood | Florida | 33021 | — |
| Novartis Investigative Site | Loxahatchee Groves | Florida | 33470 | — |
| Novartis Investigative Site | Miami | Florida | 33032 | — |
| Novartis Investigative Site | Miami | Florida | 33136 | — |
| Novartis Investigative Site | Naples | Florida | 34102 | — |
| Novartis Investigative Site | North Palm Beach | Florida | 33408 | — |
| Novartis Investigative Site | Pensacola | Florida | 32514 | — |
| Novartis Investigative Site | Port Charlotte | Florida | 33952 | — |
| Novartis Investigative Site | Sunrise | Florida | 33351 | — |
| Novartis Investigative Site | Vero Beach | Florida | 32960 | — |
| Novartis Investigative Site | West Palm Beach | Florida | 33407 | — |
| Novartis Investigative Site | Savannah | Georgia | 31406 | — |
| Novartis Investigative Site | Honolulu | Hawaii | 96817 | — |
| Novartis Investigative Site | Chicago | Illinois | 60612 | — |
| Novartis Investigative Site | Northbrook | Illinois | 60062 | — |
| Novartis Investigative Site | Indianapolis | Indiana | 46202 | — |
| Novartis Investigative Site | Des Moines | Iowa | 50314-2611 | — |
| Novartis Investigative Site | Kansas City | Kansas | 66160 | — |
| Novartis Investigative Site | Overland Park | Kansas | 66210 | — |
| Novartis Investigative Site | Alexandria | Louisiana | 71301 | — |
| Novartis Investigative Site | Baton Rouge | Louisiana | 70810 | — |
| Novartis Investigative Site | Clinton Township | Michigan | 48035 | — |
| Novartis Investigative Site | Detroit | Michigan | 48201 | — |
| Novartis Investigative Site | Golden Valley | Minnesota | 55422 | — |
| Novartis Investigative Site | Chesterfield | Missouri | 63017 | — |
| Novartis Investigative Site | Ozark | Missouri | 65721 | — |
| Novartis Investigative Site | St Louis | Missouri | 63110 | — |
| Novartis Investigative Site | Las Vegas | Nevada | 89106 | — |
| Novartis Investigative Site | Latham | New York | 12110 | — |
| Novartis Investigative Site | Charlotte | North Carolina | 28204 | — |
| Novartis Investigative Site | Raleigh | North Carolina | 27607 | — |
| Novartis Investigative Site | Winston-Salem | North Carolina | 27103 | — |
| Novartis Investigative Site | Winston-Salem | North Carolina | 27157 | — |
| Novartis Investigative Site | Cleveland | Ohio | 44195 | — |
| Novartis Investigative Site | Oklahoma City | Oklahoma | 73104 | — |
| Novartis Investigative Site | Spartanburg | South Carolina | 29303 | — |
| Novartis Investigative Site | Johnson City | Tennessee | 37604 | — |
| Novartis Investigative Site | Knoxville | Tennessee | 37920 | — |
| Novartis Investigative Site | Dallas | Texas | 75246 | — |
| Novartis Investigative Site | El Paso | Texas | 79935 | — |
| Novartis Investigative Site | Houston | Texas | 77074 | — |
| Novartis Investigative Site | Round Rock | Texas | 78681 | — |
| Novartis Investigative Site | San Antonio | Texas | 78229 | — |
| Novartis Investigative Site | San Antonio | Texas | 78258 | — |
| Novartis Investigative Site | Virginia Beach | Virginia | 23456 | — |
| Novartis Investigative Site | Green Bay | Wisconsin | 54311 | — |
| Novartis Investigative Site | Madison | Wisconsin | 53792 | — |
| Novartis Investigative Site | Milwaukee | Wisconsin | 53215 | — |
| Novartis Investigative Site | Neenah | Wisconsin | 54956 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 110 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02792218, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 1, 2021 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02792218 live on ClinicalTrials.gov.